ORPH

FDA Catalyst Company
  0%
Previous Close
Open
52 Week Low 0.5101
52 Week High 77.77
Market Cap $0
Shares 0
Float 35,312,241
Enterprise Value $-9,467,710
Volume 0
Av. Daily Volume 0
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
B of A Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/30/2021

Latest News

  1. Notes CytRx's Core Assets Are Unaffected by European Medicines Agency's Assessment of Arimoclomol

    Highlights Positive Developments Regarding Company's Core Assets, Including Aldoxorubicin

    CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S's (NASDAQ:ORPH) ("Orphazyme") announced update on the ongoing review of the Marketing Authorisation Application for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C ("NPC") by the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA"). CytRx licensed…

    View Full Article
  2. Orphazyme Intends to Request a Type C Meeting in Q2 2022

    Orphazyme Plans to Resubmit the NDA During H2 2022, Subject to FDA Discussions

    European Medicines Agency Opinion Expected in Q1 2022

    CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted Orphazyme A/S's (NASDAQ:ORPH) ("Orphazyme") announced update on the process and anticipated timelines for resubmission of its New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C ("NPC"). CytRx licensed arimoclomol to Orphazyme…

    View Full Article
  3. FDA Recommends Orphazyme Provides Supplemental Information and Analyses

    FDA Offers to have Further Interactions with Orphazyme to Identify Path to Resubmission for Arimoclomol in NPC

    CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S's (NASDAQ:ORPH) ("Orphazyme") encouraging regulatory update following its recently held Type A meeting with the U.S. Food and Drug Administration ("FDA") on arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease Type C ("NPC"). Arimoclomol, CytRx's drug candidate, was sold to Orphazyme in exchange…

    View Full Article
  4. 12-Month Study of Arimoclomol Showed a Clinically Meaningful Treatment Effect, Corresponding to a Reduction in Disease Progression

    Highlights Arimoclomol is Under Regulatory Review in Europe, With a Decision Expected in Q4 2021

    Notes Orphazyme Stated it Continues to Evaluate a Path Forward for Arimoclomol in the U.S.

    CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme") published the results from a Phase 2/3 trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C (NPC) in the peer-reviewed…

    View Full Article
  5. CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the second quarter ended June 30, 2021. In addition, CytRx recapped corporate developments as well as matters pertaining to its agreements with ImmunityBio, Inc. (NASDAQ:IBRX) ("ImmunityBio") and Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme"). The Company's 10-Q was filed today.

    Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, commented:

    "We took important steps to enhance our capital position and further strengthen our corporate governance during the second quarter. By raising gross proceeds of $10…

    View Full Article
View All News